TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LOVAZA

OMEGA-3-ACID ETHYL ESTERS
Cardiovascular Approved 2004-11-10
2
Indications
--
Phase 3 Trials
21
Years on Market

Details

Status
Prescription
First Approved
2004-11-10
Routes
ORAL
Dosage Forms
CAPSULE

Companies

Active Ingredient: OMEGA-3-ACID ETHYL ESTERS

LOVAZA Approval History

Loading approval history...

What LOVAZA Treats

1 indications

LOVAZA is approved for 1 conditions since its original approval in 2004. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypertriglyceridemia
Source: FDA Label

Drugs Similar to LOVAZA

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LOVAZA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Omega-3-acid ethyl esters capsules are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (greater than or equal to 500 mg/dL) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters and should continue this diet during treatment with omega-3-acid ethyl esters capsules. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to co...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.